Regarding PD-1 inhibitor monotherapy, a phase II clinical trial reported a pathologic complete response rate of 3.6% in HNSCC patients treated with one dose of neoadjuvant pembrolizumab monotherapy [25]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.